 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- LY007 / China Biotech Services
HIGH EFFICACY AND SAFETY OF A NOVEL ANTI-CD20 CAR-T CELL THERAPY, LY007 IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_2914;
P1
LY007 demonstrated a favorable safety profile, promising efficacy, and robust PK characteristics at doses up to DL3, with no DLTs or neurotoxicity or Grade 3+ CRS observed. LY007 achieved a 91.7% BOR, including pts with high tumor burden, prior CD19-targeted CAR T therapy and ASCT.
- LY007 / China Biotech Services
LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_3839;
65 years and prior CD19-directed CAR T therapy and ASCT. Follow-up of enrolled pts is on-going and the planned phase 2 study will start for enrollment shortly.
- LY007 / China Biotech Services
A phase 1 study of LY007, a novel anti-CD20 CAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. (Hall A; Poster Bd #: 10) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2364;
P1
In this open-label, single-arm phase 1 trial, r/r B-NHL pts were infused with LY007 in 3 dose levels (DLs) (DL1, 0.5 x 10 6 cells/ kg; DL2, 1.5 x 10 6 cells/ kg; DL3, 5.0 x 10 6 cells/ kg) based on a standard 3+3 dose escalation design after cyclophosphamide/fludarabine lymphodepletion. This phase 1 trial demonstrated that LY007 was well tolerated at the dose levels up to 5.0 x 10 6 cells/ kg and showed a favorable dose-response relationship for the treatment of r/r B-NHL.
- | LY007 / China Biotech Services
New P1 trial: An Evaluation of LY007 Cell Injection for r/r B-NHL (clinicaltrials.gov) - Apr 15, 2024
P1, N=18, Recruiting, Sponsor: Ruijin Hospital
- | LY007 / China Biotech Services
New P1 trial: An Evaluation of LY007 Cell Injection for r/r B-NHL (clinicaltrials.gov) - Feb 28, 2024
P1, N=18, Recruiting, Sponsor: Shanghai Longyao Biotechnology Inc., Ltd.
- | LY011 / China Biotech Services
New P1 trial, CAR T-Cell Therapy, Metastases: A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma (clinicaltrials.gov) - Jul 26, 2021
P1, N=18, Recruiting, Sponsor: Shanghai Longyao Biotechnology Inc., Ltd.
- | LY011 / China Biotech Services
New P1 trial, CAR T-Cell Therapy, Metastases: Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov) - Jul 18, 2021
P1, N=30, Recruiting, Sponsor: Shanghai Longyao Biotechnology Inc., Ltd.
- | LY007 / China Biotech Services
New P1 trial, CAR T-Cell Therapy, IO biomarker: The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 20, 2019
P1, N=20, Recruiting, Sponsor: Shanghai Longyao Biotechnology Inc., Ltd.
- | CD19 UCART cells / China Biotech Services
New P1 trial, CAR T-Cell Therapy: The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov) - Nov 17, 2019
P1, N=20, Recruiting, Sponsor: Shanghai Longyao Biotechnology Inc., Ltd.
- | LY007 / China Biotech Services
New P1 trial, CAR T-Cell Therapy: The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma (clinicaltrials.gov) - Jul 2, 2018
P1, N=20, Recruiting, Sponsor: Xin Wang
- | LY007 / China Biotech Services
New P1/2 trial, CAR T-Cell Therapy: Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma (clinicaltrials.gov) - Jul 2, 2017
P1/2, N=20, Recruiting, Sponsor: Shanghai Longyao Biotechnology Inc., Ltd.